良性前立腺肥大症外科治療の外科治療市場規模、シェア、産業分析レポート：タイプ別、エンドユーザー別、地域別-2025～2034年市場予測

Polaris Market Researchの最新調査によると、前立腺肥大症の外科治療市場規模は2034年までに34億1,257万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

前立腺肥大症（BPH）外科治療とは、前立腺肥大症による排尿障害を緩和するために考案された医療的介入を指し、通常、薬剤療法では十分な緩和が得られない場合に行われます。低侵襲手術への移行が進んでおり、回復が早く、術後合併症が減少しています。患者やヘルスケアプロバイダがより侵襲の少ない選択肢を好むようになるにつれ、効果的な症状管理を確保しながら組織損傷を最小限に抑える手技の採用が増加しています。この動向は、患者中心の医療を目指す広範な動きを反映したものであり、手技の転帰と全体的なQOLの向上を重視する世界の動きと一致しています。

先進的な外科技術がヘルスケアシステム全体に統合されつつあることも、成長機会を後押ししています。レーザー治療、手術用ロボット、視覚化ツールの改良などの技術革新により、BPH手術の精度と効率が向上しています。これらの進歩は手術ワークフローを合理化し、泌尿器科医が複雑な手技をより一貫性と安全性をもって行うことを可能にしています。その結果、ヘルスケアプロバイダは個別化された治療を提供できるようになり、技術的に洗練された結果重視のケアモデルへの進化を強化しています。

前立腺肥大症（BPH）外科治療市場レポートハイライト

タイプ別では、経尿道的前立腺切除術（TURP）セグメントが2024年に7億1,343万米ドルで市場をリードし、その臨床的有効性が実証され、前立腺肥大症の標準治療としての役割が確立されています。

エンドユーザー別では、外来手術の需要増とコスト効率に優れたヘルスケア提供により、外来手術センター（ASC）セグメントが予測期間中に5.7%のCAGRを記録すると予測されています。

北米のBPH外科治療市場は最大の収益シェアを占め、2024年には8億8,888万米ドルと評価されました。これは、BPH有病率の高さ、先進的な手術法の急速な導入、多額のヘルスケア支出に起因します。

アジア太平洋は2024年に21.61％の市場シェアを占め、泌尿器科医療に対する意識の高まりとヘルスケアインフラへの投資拡大に支えられています。

前立腺肥大症治療市場における世界の主要企業には、American Polyfilm, Inc.、BASF、Covestro AG、Novotex Italiana S.p.A.、RTP Company、San Fang Chemical Industry Co.

目次

第1章 良性前立腺肥大症外科治療市場の範囲更新の根拠

第2章 世界の良性前立腺肥大症外科治療市場レポート概要

• 調査範囲
• 市場セグメント分析
• 地域/国による規制シナリオ
• 市場投資シナリオ戦略
• タイプ別市場分析
  • タイプ別（2024～2034年）
  • 経尿道的前立腺切除術（TURP）
  • 前立腺尿道リフト
  • 水蒸気療法
  • レーザー療法
  • アクアブレーション療法
  • 経尿道マイクロ波温熱療法（TUMT）
  • その他
• エンドユーザー別市場分析
  • エンドユーザーによる世界の良性前立腺肥大症外科治療市場（2024～2034年）
  • 病院
  • 外来手術センター
  • クリニック
  • 在宅ケア

第3章 良性前立腺肥大症外科治療市場における促進要因、抑制要因、課題、機会

• 推進力、抑制、課題、機会の分析

第4章 世界の経済成長の動向

• 産業動向
  • SWOT分析
    • 強み
    • 弱点
    • 機会
    • 脅威
  • PESTEL分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法的
  • バリューチェーン分析
  • 競合販売データ分析
  • 2024年の治療患者数（推定）
• 潜在市場と成長ポテンシャル分析

第5章 COVID-19の影響

• COVID-19の影響
• COVID V、U、W、L分析
• COVID V分析
• COVID U分析
• COVID L分析
• COVID-19分析

第6章 企業分析

• BPH外科治療市場におけるM&Aと戦略的活動分析
• 戦略的枠組み-世界のBPH外科治療市場
• ベンダー情勢-世界のBPH外科治療市場
• 競合環境-世界のBPH外科治療市場

第7章 エグゼクティブサマリー

第8章 世界の良性前立腺肥大症外科治療市場予測、2021～2034年

• 世界の良性前立腺肥大症外科治療市場

第9章 世界の良性前立腺肥大症外科治療市場：タイプ別（2021～2034年）

第10章 世界の良性前立腺肥大症外科治療市場：エンドユーザー別（2021～2034年）

第11章 世界の良性前立腺肥大症外科治療市場：地域別（2021～2034年）

第12章 北米の良性前立腺肥大症の外科治療：国別、2021～2034年

第13章 北米の良性前立腺肥大症の外科治療（タイプ別）（2021～2034年）

第14章 北米の良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第15章 米国良性前立腺肥大症の外科治療（タイプ別）（2021～2034年）

第16章 米国良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）（単位：100万米ドル）

第17章 カナダにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第18章 カナダにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第19章 メキシコにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第20章 メキシコにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第21章 欧州のにおける良性前立腺肥大症の外科治療：国別、2021～2034年

第22章 欧州のにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第23章 欧州のにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第24章 ドイツにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第25章 ドイツにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第26章 英国における良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第27章 英国の良性前立腺肥大症外科治療（エンドユーザー別）（2021～2034年）

第28章 フランスにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第29章 フランスにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第30章 イタリアにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第31章 イタリアにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第32章 スペインにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第33章 スペインにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第34章 スイスにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第35章 スイスにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第36章 オランダにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第37章 オランダにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第38章 その他の欧州の良性前立腺肥大症の外科治療タイプ別（2021～2034年）

第39章 その他の欧州の良性前立腺肥大症の外科治療（エンドユーザー別）（2021～2034年）

第40章 アジア太平洋のにおける良性前立腺肥大症の外科治療：国別、2021～2034年（単位：100万米ドル）

第41章 アジア太平洋のにおける良性前立腺肥大症の外科治療（タイプ別）（2021～2034年）

第42章 アジア太平洋の良性前立腺肥大症外科治療（エンドユーザー別）（2021～2034年）

第43章 中国における良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第44章 中国における良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第45章 日本における前立腺肥大症の外科治療タイプ別動向（2021～2034年）

第46章 日本における良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第47章 インドにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第48章 インドにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第49章 韓国における良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第50章 韓国における良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第51章 オーストラリアにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第52章 オーストラリアにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第53章 マレーシアにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第54章 マレーシアにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第55章 インドネシアにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第56章 インドネシアにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第57章 その他のアジア太平洋の良性前立腺肥大症の外科治療タイプ別市場（2021～2034年）

第58章 その他のアジア太平洋のにおける良性前立腺肥大症の外科治療（エンドユーザー別）（2021～2034年）

第59章 中東・アフリカのにおける良性前立腺肥大症の外科治療：国別、2021～2034年（単位：100万米ドル）

第60章 中東・アフリカのにおける良性前立腺肥大症の外科的治療（タイプ別、2021～2034年）

第61章 中東・アフリカのにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第62章 サウジアラビアにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第63章 サウジアラビアにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第64章 アラブ首長国連邦における良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第65章 アラブ首長国連邦における良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第66章 南アフリカにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第67章 南アフリカにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第68章 その他の中東・アフリカの良性前立腺肥大症の外科的治療（タイプ別）（2021～2034年）

第69章 その他の中東・アフリカの良性前立腺肥大症の外科的治療（エンドユーザー別）（2021～2034年）

第70章 ラテンアメリカにおける良性前立腺肥大症の外科治療：国別、2021～2034年（単位：100万米ドル）

第71章 ラテンアメリカ良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第72章 ラテンアメリカ良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第73章 ブラジルにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第74章 ブラジルにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第75章 アルゼンチンにおける良性前立腺肥大症の外科治療（タイプ別、2021～2034年）

第76章 アルゼンチンにおける良性前立腺肥大症の外科治療（エンドユーザー別、2021～2034年）

第77章 その他のラテンアメリカ良性前立腺肥大症の外科的治療（タイプ別）（2021～2034年）

第78章 その他のラテンアメリカ良性前立腺肥大症の外科治療（エンドユーザー別）（2021～2034年）

第79章 企業プロファイル

• Alembic Pharmaceuticals Limited.
• Boston Scientific Corporation
• Asahi Kasei Corporation
• Coloplast Group
• Cook Medical
• Medifocus, Inc.
• Karl Storz Se & Co. KG
• Olympus Corporation
• Medtronic
• The Johns Hopkins Hospital
• Cleveland Clinic

第80章 結論

第81章 参考リンク

第82章 アナリストの提案と推奨事項

第83章 付録

• 調査手法
• 調査データソース
  • 二次データ
  • 二次データの主要データ
  • 一次データ
  • 一次資料の主要データ
  • プロフェッショナルリーダーによる産業洞察
  • 市場予測
  • 市場予測：トップダウンとボトムアップのアプローチ
  • 免責事項

第84章 調査範囲

LIST OF TABLES

• TABLE 1. MARKET SEGMENT
• TABLE 2. Global Benign Prostatic Hyperplasia Surgical Treatment Market Growth Rate by Type (USD Million) (2024-2034)
• TABLE 3. Global Benign Prostatic Hyperplasia Surgical Treatment Market Growth Rate by End User (USD Million) (2024-2034)
• TABLE 4. Global Benign Prostatic Hyperplasia Surgical Treatment Market - Market snapshot & key buying criteria, 2024 - 2034
• TABLE 5. Global Benign Prostatic Hyperplasia Surgical Treatment MARKET SIZE (USD MILLION), (2021-2027)
• TABLE 6. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD MILLION), (2028-2034)
• TABLE 7. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 8. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 9. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 10. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 11. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Region, (2021-2027)
• TABLE 12. Global Benign Prostatic Hyperplasia Surgical Treatment market SHARE BY Region, (2021-2027)
• TABLE 13. Global Benign Prostatic Hyperplasia Surgical Treatment marke SIZE BY Region, (2028-2034)
• TABLE 14. Global Benign Prostatic Hyperplasia Surgical Treatment market SHARE BY Region, (2028-2034)
• TABLE 15. North America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2021-2027)
• TABLE 16. North America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2028-2034)
• TABLE 17. North America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 18. North America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 19. North America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 20. North America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 21. United States Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 22. United States Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 23. United States Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 24. United States Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 25. Canada Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 26. Canada Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 27. Canada Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 28. Canada Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 29. Mexico Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 30. Mexico Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 31. Mexico Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 32. Mexico Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 33. Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY COUNTRIES, (2021-2027)
• TABLE 34. Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY COUNTRIES, (2028-2034)
• TABLE 35. Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 36. Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 37. Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 38. Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 39. Germany Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 40. Germany Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 41. Germany Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 42. Germany Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 43. UK Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 44. UK Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 45. UK Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 46. UK Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 47. France Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 48. France Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 49. France Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 50. France Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 51. Italy Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 52. Italy Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 53. Italy Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 54. Italy Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 55. Spain Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 56. Spain Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 57. Spain Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 58. Spain Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 59. Switzerland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 60. Switzerland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 61. Switzerland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 62. Switzerland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 63. Netherland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 64. Netherland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 65. Netherland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 66. Netherland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 67. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 68. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 69. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 70. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 71. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2021-2027)
• TABLE 72. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2028-2034)
• TABLE 73. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 74. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 75. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 76. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 77. China Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 78. China Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 79. China Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 80. China Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 81. Japan Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 82. Japan Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 83. Japan Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 84. Japan Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 85. India Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 86. India Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 87. India Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 88. India Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 89. South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 90. South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 91. South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 92. South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 93. Australia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 94. Australia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 95. Australia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 96. Australia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 97. Malaysia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 98. Malaysia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 99. Malaysia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 100. Malaysia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 101. Indonesia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 102. Indonesia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 103. Indonesia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 104. Indonesia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 105. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 106. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 107. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 108. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 109. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2021-2027)
• TABLE 110. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2028-2034)
• TABLE 111. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 112. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 113. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 114. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 115. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 116. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 117. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 118. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 119. UAE Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 120. UAE Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 121. UAE Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 122. UAE Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 123. South Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 124. South Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 125. South Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 126. South Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 127. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 128. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 129. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 130. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 131. Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2021-2027)
• TABLE 132. Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2028-2034)
• TABLE 133. Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 134. Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 135. Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 136. Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 137. Brazil Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 138. Brazil Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 139. Brazil Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 140. Brazil Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 141. Argentina Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 142. Argentina Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 143. Argentina Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 144. Argentina Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
• TABLE 145. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
• TABLE 146. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
• TABLE 147. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
• TABLE 148. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)

LIST OF FIGURES

• FIGURE 1. Market Overview
• FIGURE 2. DROC of Benign Prostatic Hyperplasia Surgical Treatment Analysis
• FIGURE 3. SWOT Analysis
• FIGURE 4. PESTEL Analysis
• FIGURE 5. Porter's Five Forces Analysis
• FIGURE 6. Value Chain Analysis
• FIGURE 7. COVID V, U, W and L Analysis
• FIGURE 8. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million), (2021-2027), (USD MILLION)
• FIGURE 9. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD MILLION), (2028-2034)
• FIGURE 10. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million), (2021-2027), (USD MILLION), by Region
• FIGURE 11. Global Benign Prostatic Hyperplasia Surgical Treatment MARKET SHARE, (2027), by Region
• FIGURE 12. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million), (2028-2034), (USD MILLION), by Region
• FIGURE 13. Global Benign Prostatic Hyperplasia Surgical Treatment MARKET SHARE, (2034), by Region

The benign prostatic hyperplasia surgical treatment market size is expected to reach USD 3,412.57 million by 2034, according to a new study by Polaris Market Research. The report "Benign Prostatic Hyperplasia Surgical Treatment Market Share, Size, Trends, Industry Analysis Report By Type [Transurethral Resection of the Prostate (TURP), Prostatic Urethral Lift], By End User, By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Benign prostatic hyperplasia (BPH) surgical treatment refers to medical interventions designed to relieve urinary obstruction caused by an enlarged prostate, typically when medication fails to provide adequate relief. The growing shift toward minimally invasive surgery procedures offers faster recovery and reduced postoperative complications. There is increasing adoption of techniques that minimize tissue damage while ensuring effective symptom management as patients and healthcare providers increasingly favor less invasive options. This trend reflects a broader movement toward patient-centric care and aligns with the global focus on improving procedural outcomes and overall quality of life.

The ongoing integration of advanced surgical technologies across healthcare systems boosts growth opportunities. Innovations such as laser therapies, surgical robots, and improved visualization tools are improving the precision and efficiency of BPH surgeries. These advancements streamline operative workflows and also enable urologists to perform complex procedures with greater consistency and safety. As a result, healthcare providers are better equipped to deliver personalized treatment, reinforcing the evolution toward technologically refined and outcome-driven care models.

Benign Prostatic Hyperplasia (BPH) Surgical Treatment Market Report Highlights

In terms of type, the transurethral resection of the prostate (TURP) segment led the market in 2024, valued at USD 713.43 million, owing to its proven clinical effectiveness and established role as the standard treatment for BPH.

Based on end user, the ambulatory surgery centers (ASCs) segment is expected to record the highest CAGR of 5.7% during the forecast period, driven by increasing demand for outpatient procedures and cost-efficient healthcare delivery.

The North America BPH surgical treatment market accounted for the largest revenue share, and was valued at USD 888.88 million in 2024, attributed to its high BPH prevalence, rapid adoption of advanced surgical methods, and substantial healthcare spending.

Asia Pacific held a 21.61% market share in 2024, supported by rising urological health awareness and expanding investments in healthcare infrastructure.

A few global key players in the benign prostatic hyperplasia surgical treatment market include American Polyfilm, Inc.; BASF; Covestro AG; Novotex Italiana S.p.A.; RTP Company; San Fang Chemical Industry Co., Ltd.; SWM International; The Lubrizol Corporation; Toray Industries, Inc.; and Wiman Corporation.

Polaris Market Research has segmented the benign prostatic hyperplasia surgical treatment market report on the basis of type, end user, and region:

By Type Outlook (Revenue, USD Million, 2020-2034)

Transurethral Resection of Prostate (TURP)

Prostatic Urethral Lift

Water Vapor Therapy

Laser Therapy

Aquablation Therapy

Transurethral Microwave Thermotherapy (TUMT)

Others

By End User Outlook (Revenue, USD Million, 2020-2034)

Hospitals

Ambulatory Surgery Centers and Clinics

Homecare Settings

By Regional Outlook (Revenue, USD Million, 2020-2034)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Rationale Behind Scope Update for Benign Prostatic Hyperplasia Surgical Treatment Market

2. Global Benign Prostatic Hyperplasia Surgical Treatment Market-Report Overview

• 2.1. Scope of the report
• 2.2. Market Segment Analysis
• 2.3. Regulatory Scenario by Region/Country
• 2.4. Market Investment Scenario Strategic
• 2.5. Market Analysis by Type (USD Million)
  • 2.5.1 Global Benign Prostatic Hyperplasia Surgical Treatment Market by Type (2024-2034)
  • 2.5.2 Transurethral Resection of the Prostate (TURP)
  • 2.5.3 Prostatic Urethral Lift
  • 2.5.4 Water Vapor Therapy
  • 2.5.5 Laser Therapy
  • 2.5.6 Aquablation Therapy
  • 2.5.7 Transurethral Microwave Thermotherapy (TUMT)
  • 2.5.8 Others
• 2.6. Market Analysis by End User (USD Million)
  • 2.6.1 Global Benign Prostatic Hyperplasia Surgical Treatment Market by End User (2024-2034)
  • 2.6.2 Hospitals
  • 2.6.3 Ambulatory Surgery Centers and Clinics
  • 2.6.4 Homecare Settings

3. driver restraint challenge and opportunities of Benign Prostatic Hyperplasia Surgical Treatment Market

• 3.1. Driver, Restraint, Challenge and Opportunities Analysis
  • 3.1.1 Market Driver Analysis
  • 3.1.2 Market Restraint Analysis
  • 3.1.3 Market Opportunity
  • 3.1.4 Market Challenges

4. Global Growth Trends

• 4.1. Industry Trends
  • 4.1.1 SWOT Analysis
    • 4.1.1.1 Strengths
    • 4.1.1.2 Weaknesses
    • 4.1.1.3 Opportunities
    • 4.1.1.4 Threats
  • 4.1.2 PESTEL Analysis
    • 4.1.2.1 Political Landscape
    • 4.1.2.2 Economic Landscape
    • 4.1.2.3 Social Landscape
    • 4.1.2.4 Technological Landscape
    • 4.1.2.5 Environmental Landscape
    • 4.1.2.6 Legal Landscape
  • 4.1.3 Porter's Five Forces Analysis
    • 4.1.3.1 Bargaining Power of Suppliers
    • 4.1.3.2 Bargaining Power of Buyers
    • 4.1.3.3 Threat of Substitute
    • 4.1.3.4 Threat of New Entrant
    • 4.1.3.5 Competitive Rivalry
  • 4.1.4 Value Chain Analysis
  • 4.1.5 Competitive Sales Data Analysis
  • 4.1.6 Estimated Patients Treated, 2024
• 4.2. Potential Market and Growth Potential Analysis

5. Covid-19 Impact

• 5.1. Covid-19 Impact
• 5.2. COVID V, U, W and L Analysis
• 5.3. COVID V Analysis
• 5.4. COVID U Analysis
• 5.5. COVID L Analysis
• 5.6. COVID W Analysis

6. Companies Analysis

• 6.1. M&A and Strategic Activity Analysis in BPH Surgical Treatment Market
• 6.2. Strategy Framework - Global BPH Surgical Treatment Market
• 6.3. Vendor Landscape - Global BPH Surgical Treatment Market
• 6.4. Competitive Environment - Global BPH Surgical Treatment Market

7. Exceutive Summary

8. Global Benign Prostatic Hyperplasia Surgical Treatment MARKET Forecast, 2021-2034, (USD Million)

• 8.1. Global Benign Prostatic Hyperplasia Surgical Treatment Market

9. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Type (2021-2034), (USD Million)

• 9.1. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Type (2021-2027)
• 9.2. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Type (2028-2034)

10. Global Benign Prostatic Hyperplasia Surgical Treatment Market by End User (2021-2034), (USD Million)

• 10.1. Global Benign Prostatic Hyperplasia Surgical Treatment Market by End User (2021-2027)
• 10.2. Global Benign Prostatic Hyperplasia Surgical Treatment Market by End User (2028-2034)

11. Global Benign Prostatic Hyperplasia Surgical Treatment Market by REGION (2021-2034), (USD Million)

• 11.1. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Region (2021-2027)
• 11.2. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Region (2028-2034)

12. North America Benign Prostatic Hyperplasia Surgical Treatment by COUNTRIES (2021-2034), (USD Million)

• 12.1. North America Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
• 12.2. North America Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

13. North America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 13.1. North America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 13.2. North America Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

14. North America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 14.1. North America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 14.2. North America Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

15. United States Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 15.1. United States Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 15.2. United States Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

16. United States Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 16.1. United States Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 16.2. United States Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

17. Canada Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 17.1. Canada Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 17.2. Canada Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

18. Canada Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 18.1. Canada Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 18.2. Canada Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

19. Mexico Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 19.1. Mexico Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 19.2. Mexico Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

20. Mexico Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 20.1. Mexico Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 20.2. Mexico Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

21. Europe Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2034), (USD Million)

• 21.1. Europe Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
• 21.2. Europe Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

22. Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 22.1. Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 22.2. Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

23. Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 23.1. Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 23.2. Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

24. Germany Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 24.1. Germany Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 24.2. Germany Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

25. Germany Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 25.1. Germany Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 25.2. Germany Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

26. UK Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 26.1. UK Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 26.2. UK Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

27. UK Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 27.1. UK Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 27.2. UK Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

28. France Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 28.1. France Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 28.2. France Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

29. France Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 29.1. France Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 29.2. France Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

30. Italy Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 30.1. Italy Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 30.2. Italy Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

31. Italy Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 31.1. Italy Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 31.2. Italy Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

32. Spain Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 32.1. Spain Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 32.2. Spain Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

33. Spain Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 33.1. Spain Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 33.2. Spain Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

34. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 34.1. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 34.2. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

35. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 35.1. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 35.2. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

36. Netherland Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 36.1. Netherland Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 36.2. Netherland Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

37. Netherland Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 37.1. Netherland Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 37.2. Netherland Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

38. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 38.1. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 38.2. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

39. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 39.1. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 39.2. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

40. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by COUNTRIES (2021-2034), (USD Million)

• 40.1. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
• 40.2. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

41. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 41.1. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 41.2. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

42. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 42.1. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 42.2. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

43. China Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 43.1. China Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 43.2. China Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

44. China Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 44.1. China Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 44.2. China Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

45. Japan Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 45.1. Japan Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 45.2. Japan Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

46. Japan Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 46.1. Japan Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 46.2. Japan Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

47. India Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 47.1. India Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 47.2. India Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

48. India Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 48.1. India Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 48.2. India Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

49. South Korea Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 49.1. South Korea Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 49.2. South Korea Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

50. South Korea Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 50.1. South Korea Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 50.2. South Korea Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

51. Australia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 51.1. Australia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 51.2. Australia Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

52. Australia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 52.1. Australia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 52.2. Australia Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

53. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 53.1. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 53.2. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

54. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 54.1. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 54.2. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

55. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 55.1. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 55.2. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

56. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 56.1. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 56.2. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

57. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 57.1. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 57.2. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

58. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 58.1. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 58.2. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

59. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by COUNTRIES (2021-2034), (USD Million)

• 59.1. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
• 59.2. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

60. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 60.1. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 60.2. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

61. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 61.1. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 61.2. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

62. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 62.1. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 62.2. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

63. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 63.1. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 63.2. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

64. UAE Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 64.1. UAE Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 64.2. UAE Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

65. UAE Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 65.1. UAE Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 65.2. UAE Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

66. South Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 66.1. South Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 66.2. South Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

67. South Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 67.1. South Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 67.2. South Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

68. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 68.1. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 68.2. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

69. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 69.1. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 69.2. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

70. Latin America Benign Prostatic Hyperplasia Surgical Treatment by COUNTRIES (2021-2034), (USD Million)

• 70.1. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
• 70.2. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

71. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 71.1. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 71.2. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

72. Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 72.1. Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 72.2. Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

73. Brazil Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 73.1. Brazil Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 73.2. Brazil Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

74. Brazil Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 74.1. Brazil Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 74.2. Brazil Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

75. Argentina Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 75.1. Argentina Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 75.2. Argentina Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

76. Argentina Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 76.1. Argentina Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 76.2. Argentina Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

77. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

• 77.1. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
• 77.2. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

78. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

• 78.1. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
• 78.2. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

79. Company Profiles

• 79.1. Alembic Pharmaceuticals Limited.
  • 79.1.1 Company Details
  • 79.1.2 Financial (USD Million)
  • 79.1.3 Product Summary
  • 79.1.4 Recent Developments
• 79.2. Boston Scientific Corporation
  • 79.2.1 Company Details
  • 79.2.2 Financial (USD Million)
  • 79.2.3 Product Summary
  • 79.2.4 Recent Developments
• 79.3. Asahi Kasei Corporation
  • 79.3.1 Company Details
  • 79.3.2 Asahi Kasei Financials (USD Million)
  • 79.3.3 Product Summary
• 79.4. Coloplast Group
  • 79.4.1 Company Details
  • 79.4.2 Financial (USD Million)
  • 79.4.3 Product Summary
• 79.5. Cook Medical
  • 79.5.1 Company Details
  • 79.5.2 Financial (USD Million)
  • 79.5.3 Product Summary
  • 79.5.4 Recent Developments
• 79.6. Medifocus, Inc.
  • 79.6.1 Company Details
  • 79.6.2 Financial (USD Million)
  • 79.6.3 Product Summary
  • 79.6.4 Recent Developments
• 79.7. Karl Storz Se & Co. KG
  • 79.7.1 Company Details
  • 79.7.2 Financial (USD Million)
  • 79.7.3 Product Summary
• 79.8. Olympus Corporation
  • 79.8.1 Company Details
  • 79.8.2 Financial (USD Million)
  • 79.8.3 Product Summary
  • 79.8.4 Recent Developments
• 79.9. Medtronic
  • 79.9.1 Company Details
  • 79.9.2 Financial (USD Million)
  • 79.9.3 Product Summary
• 79.10. The Johns Hopkins Hospital
  • 79.10.1 Company Details
  • 79.10.2 Financial (USD Million)
  • 79.10.3 Product Summary
  • 79.10.4 Recent Developments
• 79.11. Cleveland Clinic
  • 79.11.1 Company Details
  • 79.11.2 Financial (USD Million)
  • 79.11.3 Product Summary
  • 79.11.4 Recent Developments

80. Conclusion

81. Reference Link

82. Analyst suggestions and recommendations

83. Appendix

• 83.1. Methodology
• 83.2. Research Data Source
  • 83.2.1 Secondary Data
  • 83.2.2 Key Data from Secondary
  • 83.2.3 Primary Data
  • 83.2.4 Key Data from Primary
  • 83.2.5 Industry Insight from Professional Leaders
  • 83.2.6 Market Estimation
  • 83.2.7 Market Estimation: Top-down and Bottom-up Approach
  • 83.2.8 Legal Disclaimer

84. Research Scope